A nationwide, multicenter, retrospective, non-interventional, real-world study of clopidogrel and ticagrelor following percutaneous coronary intervention in patients in china with acute coronary syndrome
Latest Information Update: 22 Dec 2021
Price :
$35 *
At a glance
- Drugs Aspirin (Primary) ; Clopidogrel (Primary) ; Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- 22 Dec 2021 New trial record
- 13 Dec 2021 Results published in the Advances in Therapy